Bio-Path Holdings (BPTH) presents a deeply negative liquidation posture as of September 30, 2025. Total assets are $690K against total liabilities of $8.7M, yielding reported stockholders' deficit of ($8.0M). Under liquidation lens, the picture is worse: cash is $0 (100% haircut = $0 recovery), prepaid drug product of $474K receives a zero haircut under the intangibles/prepaid R&D convention (no recoverable liquidation value), other current assets of $189K may yield $170-180K at 90-95%, and PP&E gross of $1.0M is fully depreciated on book ($1.0M accumulated depreciation), suggesting minimal tangible PP&E recovery. The ROU asset of $27K mirrors the lease liability and nets to zero. All intangible value in the drug pipeline (DNAbilize platform, prexigebersen, BP1002, BP1003, BP1001-A) carries a 0% liquidation haircut per the lens framework. The MFFAIS CLV/LLV/OLV of ($8.7M) aligns with the balance sheet: current liabilities of $8.7M against essentially negligible liquid assets. Since prior filing (June 30, 2025), the balance sheet has deteriorated further: stockholders' equity moved from ($7.2M) at June 30 to ($8.0M) at September 30, driven by $976K Q3 net loss and accrual buildup. Accounts payable surged to $4.9M from $1.3M at December 31, 2024, reflecting unpaid clinical trial, legal, and manufacturing vendors. Accrued liabilities reached $3.0M. The March 2025 Promissory Notes ($261K aggregate principal) were in default as of September 30, 2025, triggering a 150% default penalty provision and conversion rights at 65% of lowest 10-day bid price. The April 2025 Promissory Note defaulted subsequent to period end. A derivative liability of $343K was recognized on the defaulted notes under ASC 815. The Company implemented a company-wide operational pause on June 24, 2025, furloughed most employees, was delisted from Nasdaq in February 2025, and the filing itself was not reviewed by an independent auditor—an explicit SEC deficiency disclosure. Management acknowledges cash of $0.0M at September 30, 2025 and substantial doubt as to going concern. The filing discusses a new Series S Preferred Stock class (51 shares, each carrying 1% of fully diluted voting power) issued to restructuring advisor Steel Giants Advisors LLC in January 2026, but this capital structure change is not separately XBRL-tagged in this filing and appears only in the subsequent events narrative.
▼ Community Notes